Skip to main content

Table 1 Demographic data and baseline characteristics of randomized patients

From: Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease

 

Salmeterol n=184

Salmeterol + Fluticasone n=189

Age, years

64.0

(7.7)

63.0

(7.9)

Male

137

(75)

138

(73)

Current smoker

64

(35)

74

(39)

Pack-years smoked

37.8

(18.1)

34.8

(17.4)

Prebronchodilator FEV1 % predicted*

48.2

(12.9)

47.4

(13.9)

Reversibility, % predicted FEV1*

4.9

(4.1)

4.7

(3.5)

CCQ Total score *

1.7

(0.9)

1.6

(0.8)

CCQ functional

1.7

(1.1)

1.7

(1.0)

CCQ emotional

0.5

(0.9)

0.5

(0.8)

CCQ symptoms

2.3

(1.1)

2.1

(0.9)

  1. * at randomization. FEV1: forced expiratory volume in one second. Data are presented as number (%) or mean (SD). CCQ= Control of COPD Questionnaire; Reversibility was assessed by inhaling 400μg salbutamol using a Volumatic® spacer.